{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:15:53Z","timestamp":1788261353614,"version":"build-2803163510"},"reference-count":56,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.1080\/14737140.2026.2665840","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:30:21Z","timestamp":1777552221000},"page":"1079-1092","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An evaluation of avutometinib in combination with defactinib for\n                    <i>KRAS<\/i>\n                    -mutated recurrent low-grade serous ovarian cancer"],"prefix":"10.1080","volume":"26","author":[{"given":"Vivek","family":"Podder","sequence":"first","affiliation":[{"name":"Mount Sinai Medical Center","place":["Miami Beach, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Slomovitz","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center","place":["Miami Beach, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":false,"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"US Oncology Network","place":["Georgetown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e15"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000227787.24587.d1"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004610"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.0873"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34753"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00952-5"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34627-5"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.5545"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005919"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4183"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317733984"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011254"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2020.11.021"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2582805"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01348"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020458"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14518"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.0632"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70572-7"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02175-9"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.03.001"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.01.022"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.03.011"},{"key":"e_1_3_4_28_1","unstructured":"NCCN Guidelines Panel. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 3. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2026 [cited 2026 Apr 9]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000190"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.01.027"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03869-x"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.11.016"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02190"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01164"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107207118"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3937"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.03.011"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0282-y"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0543"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.10.033"},{"key":"e_1_3_4_42_1","unstructured":"U.S. Food and Drug Administration. AVMAPKI\u2122\u2013FAKZYNJA\u2122 co-pack: prescribing information. 2025. [cited 2026 Mar 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219616s000lbl.pdf"},{"key":"e_1_3_4_43_1","unstructured":"Administration USFDA. Trametinib (mekinist) tablets: prescribing information: U.S. Food and Drug administration. 2022 [cited 2026 Mar 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204114s024lbl.pdf"},{"key":"e_1_3_4_44_1","unstructured":"Administration USFDA. MEKTOVI\u00ae (binimetinib) tablets for oral use: prescribing information: U.S. Food and Drug administration. 2018 [cited 2026 Feb 3]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210498lbl.pdf"},{"key":"e_1_3_4_45_1","unstructured":"Administration USFDA. KOSELUGO\u00ae (selumetinib) capsules for oral use: prescribing information: U.S. Food and Drug administration. 2020 [cited 2026 Mar 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213756s000lbl.pdf"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03763-y"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00112"},{"key":"e_1_3_4_48_1","unstructured":"Administration USFDA. FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer: U.S. Food and Drug administration. 2025 [cited 2026 Mar 14]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.01.028"},{"issue":"5","key":"e_1_3_4_50_1","doi-asserted-by":"crossref","first-page":"B025","DOI":"10.1158\/1557-3125.RAS23-B025","article-title":"Abstract B025: the RAF\/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of kras G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK","volume":"21","author":"Coma S","year":"2023","unstructured":"Coma S, Musteanu M, Caffarra C, et al. Abstract B025: the RAF\/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of kras G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK. Mol Cancer Res. 2023;21(5 Suppl):B025\u2013B.","journal-title":"Mol Cancer Res"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"e_1_3_4_52_1","unstructured":"ClinicalTrials.gov. Identification of treatment concentrations of defactinib or VS-6766 for the treatment of patients with glioblastoma: NLM (US). 2025. [cited 2026 Mar 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05798507"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3010-1"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30464-2"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3363"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0210-8"},{"key":"e_1_3_4_57_1","unstructured":"ClinicalTrials.gov. A study of avutometinib defactinib and letrozole in people with low-grade serous ovarian cancer. CHAMELEON: ClinicalTrials.gov; 2025 [cited 2026 Mar 14]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06394804"},{"issue":"5","key":"e_1_3_4_58_1","first-page":"205","article-title":"Redefining the standard of care for low-grade serous ovarian cancer","volume":"22","author":"Manning-Geist BL","year":"2024","unstructured":"Manning-Geist BL, Cantor T, O\u2019Cearhbhaill RE, et al. Redefining the standard of care for low-grade serous ovarian cancer. Clin Adv Hematol Oncol. 2024;22(5):205\u2013226.","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2665840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737140.2026.2665840","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2665840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:28:34Z","timestamp":1788258514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2026.2665840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,2]]}},"alternative-id":["10.1080\/14737140.2026.2665840"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2026.2665840","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}